Image : http://www.flickr.com
Biopharmaceuticals are nothing but a related branch of pharmaceutical Engineering. They deal with the production of medicines by applying the concepts of biotechnology. Some of the living organisms' including plants are great source of substances used to prepare several medications. These plants deal with such organisms and botanical sources.
The demand for safe, recombinant pharmaceutical proteins is a rapidly expanding field. The world market for biotech has undergone rapid expansion since its emergence about two decades ago and it is still thriving. There has been a huge profit obtained from growth hormones, insulin and red-blood-cell stimulating agents and accelerating the R&D and the market in targeting a wider range of diseases, from growth deficiency to arthritis, multiple sclerosis and orphan diseases.
Currently, some 80 biopharmaceuticals are already in the market and more than 500 are under development stage at different clinical level. Among them, the recombinant antibodies (rAbs) and their derivative are finding even more promising clinical uses. Biotechnological advances have enabled the development of humanized and fully human antibodies, with improved therapeutic potential. Therapeutic monoclonal antibodies (Mabs) have immense potential and accounts for around 40% of total production of biopharmaceuticals. Clear clinical applications have been identified in cancer and other key medical areas such as transplants, auto-immunity and cardiovascular disorders.
Biotechnology virtually holds unlimited potential for drug production. Constant advances in pathogenesis can potentially solve any diseases, with a continuous increase in life expectancy. In principle, all diseases and traumas might be successfully treated with specific biopharma. However, this requires a long development time and high investment cost. But, the production of biopharmaceuticals in plants may be able to significantly reduce the production costs with increased safety. At present, major therapeutic areas include biopharmaceuticals for oncology and blood disorders which are market leaders as well as anti-infectives and vaccines.
Guidelines for the quality of biological active substances produced by stable transgene expression in higher plants have been published by medicine agencies. These guidelines regulate each step of production process, from biopharma genetic development to manufacturing and controls. These guidelines are expected to provide directives and regulations to attract investors and to boost research.
For more information on Biopharmaceutical plants and the benefits of Pharmaceutical engineering please visit the mentioned website.
No comments:
Post a Comment